S&P TEST

SWOT & PESTLE.com

GLAXOSMITHKLINE PLC SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. Topurchase reprints of this document, please email support@swotandpestle.com.



Company Name: GlaxoSmithKline Plc

Company Sector: Pharmaceuticals and Consumer Healthcare

Operating Geography: United Kingdom, Global

About the Company:

GSK is a global biopharmaceutical company with its headquarters located in London, United Kingdom. As of 2023, the company boasts an extensive and dedicated workforce of 69,400 spread across various countries, working towards a common purpose of advancing healthcare and making a transformative impact on patient's lives. With a rich history of pioneering medical breakthroughs and delivering innovative healthcare solutions, GSK has been at the forefront of addressing unmet medical needs for decades. The company's core business revolves around discovering, developing, and manufacturing vaccines, medicines, and consumer healthcare products. Its diversified portfolio covers a wide range of therapeutic areas, including infectious diseases, oncology, respiratory, immunology, and more. On May 16, 2022, the company underwent a name change from GlaxoSmithKline to GSK.

With 37 manufacturing sites and a vast network of over 24,000 suppliers, GSK ensures the efficient production and supply of its products to meet the healthcare demands of patients across the globe. The company's vaccines division is a global leader, delivering millions of vaccine doses every day. Approximately 40% of the world's children receive a GSK vaccine annually. GSK has been ranked 1st in the Access to Medicine Index and achieved a remarkable 2nd position in the pharmaceuticals industry according to the S&P Global Corporate Sustainability Assessment with a score of 86 as of 17th February 2023. These achievements further solidify GSK's position as a key player in the pharmaceutical industry, committed to making a positive impact on society and the environment.

As a leading biopharmaceutical company, GSK's unique selling proposition lies in its robust research and development capabilities, which have led to numerous groundbreaking discoveries and innovative treatments. Guided by its vision to unite science, technology, and talent, GSK's mission is to positively impact the health of 2.5 billion people by the end of 2030. With this mission in mind, GSK strives to deliver life-changing treatments and preventive solutions to patients worldwide.

Revenue:

£ 29.3 billion - FY ending 31st Dec 2022 (y-o-y growth -14.08%)

£ 34.1 billion - FY ending 31st Dec 2021



SWOT Analysis:

The SWOT Analysis for GlaxoSmithKline Plc is given below:

Strengths	Weaknesses
1.Global sales and marketing infrastructure	1.GSK's brand image is affected by the health
2.Strategic collaborations and acquisitions	care settlements in the US and bribery charges:
driving innovation and growth in healthcare:	
3.Strong financial performance and strategic	
initiatives:	
4.Advancing healthcare through research and	
development innovation and collaboration:	
5.Strengthening the manufacturing network to	
support growth in vaccines and specialty	
medicines	
Opportunities	Threats
Opportunities 1.Growth opportunity in the vaccines business	Threats 1.Intense competition from Generic drugs
1.Growth opportunity in the vaccines business	1.Intense competition from Generic drugs
1.Growth opportunity in the vaccines business 2.Growth opportunity in the HIV and	1.Intense competition from Generic drugs 2.Drug pricing controls leading to cost
1.Growth opportunity in the vaccines business 2.Growth opportunity in the HIV and infectious disease business	1.Intense competition from Generic drugs 2.Drug pricing controls leading to cost containment pressures
1.Growth opportunity in the vaccines business 2.Growth opportunity in the HIV and infectious disease business 3.Opportunities in the emerging markets	1.Intense competition from Generic drugs 2.Drug pricing controls leading to cost containment pressures 3.Challenges to patent protection by
1.Growth opportunity in the vaccines business 2.Growth opportunity in the HIV and infectious disease business 3.Opportunities in the emerging markets driven by the increasing awareness about	1.Intense competition from Generic drugs 2.Drug pricing controls leading to cost containment pressures 3.Challenges to patent protection by
1.Growth opportunity in the vaccines business 2.Growth opportunity in the HIV and infectious disease business 3.Opportunities in the emerging markets driven by the increasing awareness about healthcare needs	1.Intense competition from Generic drugs 2.Drug pricing controls leading to cost containment pressures 3.Challenges to patent protection by
1.Growth opportunity in the vaccines business 2.Growth opportunity in the HIV and infectious disease business 3.Opportunities in the emerging markets driven by the increasing awareness about healthcare needs 4.UK grants groundbreaking authorization for	1.Intense competition from Generic drugs 2.Drug pricing controls leading to cost containment pressures 3.Challenges to patent protection by



PESTLE Analysis:

The PESTLE Analysis for GlaxoSmithKline Plc is given below:

Political	Economical
1.Adapting to geopolitical tensions in health	1.Rising pressure on healthcare costs:
and life sciences industries:	2.Impact of global economic conditions on the
2.Impact of Russia-Ukraine war:	pharmaceutical industry
3.Government segments outpace commercial	
segment:	
Social	Technological
1.Growing and aging populations worldwide:	1.Track and trace technology to remove
2.Growing demand for preventive healthcare	counterfeits
products and medications	2.Growing medical research and development
	3.Blockchain and AI (Artificial Intelligence) to
	enable data decentralization opening up new
	opportunities
	4.Digital transformation to improve patient
	engagement, optimize supply chains and
	enhance marketing strategies:
Legal	Environmental
1.Managing Intellectual property rights (IPR)	1.Focus on managing environmental impact
in pharma:	2.Sustainable initiatives and industry
2.Growing demand for preventive healthcare	challenges
products and medications	

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **GlaxoSmithKline Plc** SWOT & PESTLE Analysis is a paid report at **12.53 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support: support@swotandpestle.com